Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioblastoma × sacituzumab govitecan × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 17 Triple Negative Breast Neoplasms 12 Carcinoma, Non-Small-Cell Lung 5 Lung Neoplasms 4 Carcinoma, Transitional Cell 4 Urinary Bladder Neoplasms 3 Neoplasm Metastasis 3 Brain Neoplasms 3 Salivary Gland Neoplasms 2 Uterine Cervical Neoplasms 1 Urothelial Bladder Carcinoma 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Mouth Neoplasms 1 Metastatic Urothelial Cancer 1 Laryngeal Neoplasms 1 Klatskin Tumor 1 Hypopharyngeal Neoplasms 1 HER2-negative Breast Cancer 1 Glioblastoma 1 Esophageal Squamous Cell Carcinoma 1

Interventions

Temozolomide 140 Bevacizumab 80 Radiotherapy 69 Magnetic Resonance Spectroscopy 22 Radiation 18 Irinotecan 18 pembrolizumab 17 Lomustine 16 Carmustine 15 Surgical Procedures, Operative 13 Nivolumab 11 Erlotinib Hydrochloride 11 sargramostim 9 Thalidomide 9 Specimen Handling 9 Chemotherapy, Adjuvant 9 Aminolevulinic Acid 9 Carboplatin 8 Cilengitide 7 Sunitinib 6 Immunoglobulin G 6 Etoposide 6 Disulfides 6 Cyclophosphamide 6 antineoplaston AS 2-1 5 antineoplaston A10 5 Radiotherapy, Intensity-Modulated 5 Radiosurgery 5 Metformin 5 Imatinib Mesylate 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04559230 2025-08-05

Sacituzumab Govitecan in Recurrent Glioblastoma

The University of Texas Health Science Center at San Antonio

Phase 2 Recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡